Trial Profile
A phase I study of subcutaneous 'CYT 107' (interleukin 7) in refractory metastatic melanoma or renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-7 (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- 25 Jul 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 01 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Dec 2009 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.